A new standard in prenatal testing is about to be born…

The challenge

Millions of babies are born every year with severe genetic diseases.
Existing non-invasive screening methods allow the detection of less than 10% of known genetic disorders. Invasive genetic tests are risky, late, and thus rarely used.

10% disorders detected today

Undetected

Solution

1

Cell free DNA is circulating in maternal blood

2

Identifai’s technology enables the isolation, examination and analysis of the fetus’s cell free DNA

3

Identifai’s novel paradigm and digital solutions allow early, non-invasive and comprehensive prenatal genetic testing

Technology

Identifai’s cutting edge bioinformatics technology offers an early and comprehensive prenatal screening test for genetic syndromes. Using a simple blood test from the mother during the first trimester of the pregnancy, our proprietary data science algorithms provide a high-resolution yet comprehensive perspective of the fetus’s health at an early stage of the pregnancy.

How does it work?

1. A blood draw is taken from the mother

2. The sample is sequenced – fetal and maternal DNAs are still mixed
3. Fetus’s DNA is digitally isolated using Identifai’s computational process
4. Fetus’s DNA is reconstructed at high resolution, and actionable variants (mutations) are located and analyzed
5. A genetic report is generated

Current solutions

Current technologies are either invasive, e.g. amniotic fluid test, or limited to only ~10% of genetic conditions, mainly chromosomal abnormalities.

Detect chromosomal conditions

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Our solution

Identifai’s technology offers the only available clinical solution for an early, non-invasive and comprehensive prenatal genetic screening, from point mutations to chromosomal anomalies.

Full

Coverage

Maximal

Resolution

News & Publications

Prenatal screening by cell-free DNA (cfDNA) involves sequencing fetal cfDNA in maternal blood, but it is mostly limited to low-resolution...
Single-nucleotide variants (SNVs) are the leading cause of inherited single-gene disorders (SGDs). Identifying SNVs in a non-invasive prenatal...
Birth defects are innate developmental errors, encompassing structural or functional irregularities that impact physical, mental, and social wellbeing...

About Us

EYAL MILLER

CEO
MBA, MA, with 27 years of global experience in Medtech, he has driven innovation at Stratasys, Common Sense, and Nucleix. Led 3D platforms for medical models (Stratsys), spearheaded a noninvasive diagnostic tool for bladder cancer (Nucleix) and directed pioneering efforts in Dental graft technology as CEO at Ivory Graft

PROF. NOAM SHOMRON PhD

CSO
Head of the Functional Genomics Lab at Tel Aviv University’s Medical School. Director of the Djerassi Institute of Oncology. Co-founder of several Biotech companies

NOA LISCOVITCH PhD

Head of Research
PhD in Computational neuro-genomics with expertise in genome engineering and NGS data analysis. Led impactful projects published in top-tier journals. Winner of highly competitive prizes and grants during post-doctoral studies at NYU and NYGC.

GILAD MAGNAZI

COO
MEng in Systems Engineering, B.Sc. in Biomedical Engineering, MBA. Served as CEO and Board member at Empress Medical, led development projects, operations and clinical validation of innovative products in the biomedical industry.

TOM RABINOWITZ MD PhD

CTO
MD PhD in computational genomics, specifically in detection of diseases through advanced algorithms and AI. For his work, he won several prizes, scholarships and awards.

RAVIT MESIKA

Data Scientist
Data Scientist specializing in Machine Learning algorithms. Experienced in developing end-to-end data pipelines tailored for various business models. M.Sc. in Biochemistry with expertise in Bioinformatics and Neuroscience. Won the Polek prize and several other awards.

DOLEV RAHAT

Senior Bioinformatician
Bioinformatician with expertise in NGS analysis for clinical applications, cell free DNA analysis and machine learning. M.Sc. in bioinformatics, participated in multiple projects leading to discovery of novel disease genes in cancer and neurological disorders.

SHAHAR KOREN PhD

Senior Bioinformatician
Bioinformatician and data scientist specializing in computational genomics, analysis of complex data sets and multi-omics data. Experienced in NGS analysis, exploratory data analysis of genetic variance, predictive models. PhD in Genetics, winner of the Mochrik Prize.

OREN TADMOR

Head of Product
Technological leader and manager of multi-disciplinary teams. 25 years experience in IAF as large-scale technological projects manager and F-16 squadron commander. Experience as EIR in Venture Studio ShizimVS. B Sc. Electrical Engineering.

LILACH SCHNEOR

Bioinformatician
Bioinformatician experienced in analysis of sequencing data and genetic datasets, utilizing computational tools, statistical analysis and machine learning. M.Sc. in Genetics with specialization in Bioinformatics.

SAPIR SAAR

Junior Bioinformatician
Junior Bioinformatician focusing on market research, genetic data pre-processing and R&D support. B.Sc. in Biomedical Engineering, special interests include computational genomics and systems biology.

IDO BEN-ZVI

Software Developer
B.Sc. in Computer Science, Masters in Biotechnology and computational models. Experienced developer in the biotechnology industry, point-of-care products, design and implementation of technological pipelines.

ROTEM SHOMRAT CPA

CFO
Rotem has more than 10 years of experience in accounting firms, High-Tech & communication industry. Prior to this position, she has worked in the finance team of Nice Systems, a global NASDAQ traded company, and other private fast-growing companies.

YOSSI BORNSTEIN

Chairman
CEO and the founder of Shizim Group. Has played key roles in the Israeli & International biomed industry. Former General Manager of Bristol-Myers Squibb (Israel). Co-Founder & Director of Microbot Medical (NASDAQ: MBOT) and XACT Robotics. Director of Can-Fite BioPharma (NASDAQ: CANF).

Collaborators

Contact Us